302 related articles for article (PubMed ID: 23470503)
1. Do inflammatory bowel disease therapies cause cancer?
Mason M; Siegel CA
Inflamm Bowel Dis; 2013 May; 19(6):1306-21. PubMed ID: 23470503
[TBL] [Abstract][Full Text] [Related]
2. Cancer and immunomodulators in inflammatory bowel diseases.
Biancone L; Onali S; Petruzziello C; Calabrese E; Pallone F
Inflamm Bowel Dis; 2015 Mar; 21(3):674-98. PubMed ID: 25545375
[TBL] [Abstract][Full Text] [Related]
3. Monitoring for Extra-Intestinal Cancers in IBD.
Sifuentes H; Kane S
Curr Gastroenterol Rep; 2015 Nov; 17(11):42. PubMed ID: 26364836
[TBL] [Abstract][Full Text] [Related]
4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
5. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
7. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
Kopylov U; Vutcovici M; Kezouh A; Seidman E; Bitton A; Afif W
Inflamm Bowel Dis; 2015 Aug; 21(8):1847-53. PubMed ID: 25993693
[TBL] [Abstract][Full Text] [Related]
8. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?
Lakatos PL; Miheller P
Curr Drug Targets; 2010 Feb; 11(2):179-86. PubMed ID: 20210767
[TBL] [Abstract][Full Text] [Related]
9. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
Lee J; Clarke K
Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
[TBL] [Abstract][Full Text] [Related]
11. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
Hudesman D; Lichtiger S; Sands B
Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
[TBL] [Abstract][Full Text] [Related]
12. Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.
Kalman RS; Hartshorn K; Farraye FA
Inflamm Bowel Dis; 2015 Feb; 21(2):428-35. PubMed ID: 25251059
[TBL] [Abstract][Full Text] [Related]
13. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
[TBL] [Abstract][Full Text] [Related]
15. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
17. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
18. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same?
Garg SK; Loftus EV
Curr Opin Gastroenterol; 2016 Jul; 32(4):274-81. PubMed ID: 27152873
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.
Masunaga Y; Ohno K; Ogawa R; Hashiguchi M; Echizen H; Ogata H
Ann Pharmacother; 2007 Jan; 41(1):21-8. PubMed ID: 17200426
[TBL] [Abstract][Full Text] [Related]
20. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]